Effective and safe off-label use of caplacizumab treatment in a middle-aged obese male.

ADAMTS13 Protein Humans Male Middle Aged Obesity / complications Off-Label Use Plasma Exchange Purpura, Thrombotic Thrombocytopenic / drug therapy Single-Domain Antibodies / therapeutic use
ADAMTS13 Caplacizumab Outcome Purpura thrombotique thrombocytopénique Résultat Thrombotic thrombocytopenic purpura

Journal

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
ISSN: 1953-8022
Titre abrégé: Transfus Clin Biol
Pays: France
ID NLM: 9423846

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 14 10 2020
revised: 23 11 2020
accepted: 26 11 2020
pubmed: 8 12 2020
medline: 29 10 2021
entrez: 7 12 2020
Statut: ppublish

Résumé

This study shows clinical efficacy and safety profile of an off-label use of caplacizumab for the treatment of immune-mediated thrombotic thrombocytopenic purpura in a middle-aged obese male patient manifesting aphasia, weakness and unconsciousness. Routine blood tests revealed haemolytic anaemia, severe thrombocytopenia (platelet count=20×10

Identifiants

DOI: 10.1016/j.tracli.2020.11.003 PMID: 33285299
pubmed: 33285299
pii: S1246-7820(20)30162-2
doi: 10.1016/j.tracli.2020.11.003
pii:
doi:

Substances chimiques

Single-Domain Antibodies 0
caplacizumab 2R27AB6766
ADAMTS13 Protein EC 3.4.24.87

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-91

Informations de copyright

Copyright © 2020 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

A Ostuni (A)

Transfusion Medicine, Azienda Ospedaliero Universitaria Consorziale Policlinico, Bari, Italy.

G Tiscia (G)

Thrombosis and Haemostasis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

C Battista (C)

Transfusion Medicine, Azienda Ospedaliero Universitaria Consorziale Policlinico, Bari, Italy.

G Favuzzi (G)

Thrombosis and Haemostasis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

V Montinaro (V)

Nephrology, Dialysis and Transplantation Unit, DETO, University of Bari "Aldo Moro", Bari, Italy.

V Pronzo (V)

Nephrology, Dialysis and Transplantation Unit, DETO, University of Bari "Aldo Moro", Bari, Italy.

F Cappucci (F)

Thrombosis and Haemostasis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

L Fischetti (L)

Thrombosis and Haemostasis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy.

L Gesualdo (L)

Nephrology, Dialysis and Transplantation Unit, DETO, University of Bari "Aldo Moro", Bari, Italy.

E Grandone (E)

Thrombosis and Haemostasis Unit, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (Foggia), Italy; Ob/Gyn Department of the First I.M. Sechenov Moscow State Medical University, Moscow, Russian Federation. Electronic address: e.grandone@operapadrepio.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Scléroprotéines › Protéines de la matrice extracellulaire › Protéines ADAMTS › Protéine ADAMTS13 › Effective and safe off-label use of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Effective and safe off-label use of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Effective and safe off-label use of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Obésité › Effective and safe off-label use of...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Utilisation hors indication › Effective and safe off-label use of...
questionsmedicales.fr › Procédures de chirurgie opératoire › Circulation extracorporelle › Plasmaphérèse › Échange plasmatique › Effective and safe off-label use of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations cutanées › Purpura › Purpura thrombopénique › Purpura thrombotique thrombocytopénique › Effective and safe off-label use of...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Fragments d'immunoglobuline › Fragments Fab d'immunoglobuline › Anticorps à domaine unique › Effective and safe off-label use of...